Showing 1 - 3 of 3 Hematologic Cancers
A PHASE Ib STUDY OF THE SAFETY AND

Status: Enrolling

Investigator: Sai ravi kiran Pingali

Study Coordinator: Sharell Cornett-Risher

Phone: 713.441.3250

This study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab alone and in combination with various immunomodulatory agents in patients with relapsed/refractory multiple myeloma or patients with myeloma who have measureabl ... Read more >

ASTX727 vs IV Decitabine in MDS and CMML

Status: Enrolling

Investigator: Jasleen Randhawa

Study Coordinator: Ashley Towne

Phone: 346.238.2006

Multicenter, randomized, open-label, crossover PK study of ASTX727 versus IV decitabine. Adult subjects who are candidates to receive IV decitabine will be randomized 1:1 to receive the ASTX727 tablet Daily×5 in Cycle 1 followed by IV decitabine ... Read more >

CAMN107A study of treatment-free remission in chronic myeloid leukemia in chronic phase CML-CP patients

Status: Open Not Enrolling

Investigator: Sai ravi kiran Pingali

Study Coordinator: Erick Villarreal-Williams

Phone: 713.441.9775

A clinical research study to find out if it is safe to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients. Patients who started treatment with imatinib (Gleevec) when they were first diagnosed with CML, then switched to ... Read more >